BR0012082A - Formulação farmacêutica para administração compreendendo morfina e seu uso - Google Patents

Formulação farmacêutica para administração compreendendo morfina e seu uso

Info

Publication number
BR0012082A
BR0012082A BR0012082-0A BR0012082A BR0012082A BR 0012082 A BR0012082 A BR 0012082A BR 0012082 A BR0012082 A BR 0012082A BR 0012082 A BR0012082 A BR 0012082A
Authority
BR
Brazil
Prior art keywords
morphine
pharmaceutical formulation
administration
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR0012082-0A
Other languages
English (en)
Inventor
Raja G Achari
Charanjit R Behl
Jorge C Demeireles
Ramneik Dua
Vincent D Romeo
Anthony P Sileno
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of BR0012082A publication Critical patent/BR0012082A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçãO FARMACêUTICA PARA ADMINISTRAçãO COMPREENDENDO MORFINA E SEU USO". A presente invenção refere-se a uma formulação farmacêutica para administração intranasal compreendendo morfina ou seu sal farmaceuticamente aceitável a um pH de cerca de 3,0 a cerca de 7,0. Tais formulações provêem absorção aumentada de morfina ou de seu sal farmaceuticamente aceitável. Numa concretização, a presente invenção provê um método para provocar uma resposta analgésica ou anestésica num mamífero que inclui administrar nasalmente uma quantidade terapeuticamente eficaz de morfina ou de seu sal farmaceuticamente aceitável a um pH de cerca de 3,0 a cerca de 7,0.
BR0012082-0A 1999-06-16 2000-05-23 Formulação farmacêutica para administração compreendendo morfina e seu uso BR0012082A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (en) 1999-06-16 2000-05-23 Pharmaceutical formulations and methods comprising intranasal morphine

Publications (1)

Publication Number Publication Date
BR0012082A true BR0012082A (pt) 2002-05-07

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012082-0A BR0012082A (pt) 1999-06-16 2000-05-23 Formulação farmacêutica para administração compreendendo morfina e seu uso

Country Status (30)

Country Link
US (1) US6677346B1 (pt)
EP (2) EP1183027A4 (pt)
JP (1) JP2003501467A (pt)
KR (1) KR20020016831A (pt)
AU (1) AU774175B2 (pt)
BG (1) BG106221A (pt)
BR (1) BR0012082A (pt)
CA (1) CA2374877C (pt)
CZ (1) CZ20014399A3 (pt)
DE (1) DE10084709T1 (pt)
DK (1) DK200101859A (pt)
EE (1) EE200100677A (pt)
ES (1) ES2197792B1 (pt)
FI (1) FI20012462A (pt)
GB (1) GB2367005A (pt)
HR (1) HRP20010926A2 (pt)
HU (1) HUP0201856A3 (pt)
IS (1) IS6202A (pt)
LT (1) LT4976B (pt)
LU (1) LU90859B1 (pt)
LV (1) LV12859B (pt)
MX (1) MXPA01012879A (pt)
NO (1) NO20015931L (pt)
NZ (1) NZ515783A (pt)
PL (1) PL352556A1 (pt)
SE (1) SE0104203D0 (pt)
SI (1) SI20850A (pt)
SK (1) SK18172001A3 (pt)
TR (1) TR200103613T2 (pt)
WO (1) WO2000076506A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
AU2002303148A1 (en) * 2001-06-29 2003-03-03 Leon J. Lewandowski Individualized addiction cessation therapy
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
US20090317377A1 (en) 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
BRPI0720434A2 (pt) * 2006-12-22 2014-01-07 Sigma Tau Ind Farmaceuti Gel útil para liberação de fármacos oftálmicos
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
AU2012386221A1 (en) 2012-07-26 2015-02-26 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
EP3082817A4 (en) * 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP4331670A3 (en) 2015-01-07 2024-05-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
EP3528873A2 (en) * 2016-10-21 2019-08-28 Somniferum Labs LLC Apparatus for controlled delivery of opioid and other medications
EP3697381B1 (en) * 2017-10-20 2023-06-07 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
WO1994022445A2 (en) * 1993-03-26 1994-10-13 Merkus Franciscus W H M Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
EP1006969A1 (en) * 1996-09-27 2000-06-14 Nastech Pharmaceutical Co. Intranasal formulations for promoting sleep and method of using the same

Also Published As

Publication number Publication date
EE200100677A (et) 2003-02-17
PL352556A1 (en) 2003-08-25
HUP0201856A3 (en) 2004-12-28
US6677346B1 (en) 2004-01-13
NO20015931D0 (no) 2001-12-04
SE0104203L (sv) 2001-12-14
CA2374877C (en) 2004-04-13
LT2001119A (en) 2002-07-25
KR20020016831A (ko) 2002-03-06
IS6202A (is) 2001-12-14
HUP0201856A1 (en) 2002-09-28
EP1419774A1 (en) 2004-05-19
DE10084709T1 (de) 2002-09-26
BG106221A (en) 2002-08-30
AU774175B2 (en) 2004-06-17
ES2197792A1 (es) 2004-01-01
FI20012462A (fi) 2002-01-16
TR200103613T2 (tr) 2004-08-23
JP2003501467A (ja) 2003-01-14
EP1183027A4 (en) 2003-02-05
LV12859B (en) 2002-12-20
CA2374877A1 (en) 2000-12-21
GB0128383D0 (en) 2002-01-16
SE0104203D0 (sv) 2001-12-14
ES2197792B1 (es) 2005-05-01
LU90859B1 (en) 2002-01-24
SK18172001A3 (sk) 2002-07-02
LT4976B (lt) 2002-12-30
NO20015931L (no) 2002-02-08
HRP20010926A2 (en) 2003-04-30
EP1183027A1 (en) 2002-03-06
WO2000076506A1 (en) 2000-12-21
CZ20014399A3 (cs) 2002-06-12
MXPA01012879A (es) 2003-06-24
GB2367005A (en) 2002-03-27
SI20850A (sl) 2002-10-31
DK200101859A (da) 2001-12-12
AU5156100A (en) 2001-01-02
NZ515783A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NZ508526A (en) Opioid formulations for treating pain
ITRM910922A1 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
BR0108584A (pt) Formulações contendo um fármaco anticolinérgico para o tratamento da broncopneumopatia crÈnica obtrutiva
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
ID29530A (id) Sediaan obat-obatan untuk penggunaan eksternal menggunakan zat-zat non-steroid anti-peradangan dan analgesik
SE9601528D0 (sv) Transdermally administered dextromethorphan as antitissue agent
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
DE59914183D1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
BRPI0408113A (pt) métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica
BR9910201A (pt) Sistema terapêutico transdérmico para emprego de candesartan
GT199900171A (es) Concentrado oral de sertralina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.